Alpha Profiles · Company Profile

BeOne Medicines Ltd.

Canonical company identity and public leadership record.

https://registry.alpha.ac/companies/beone-medicines-ltd

Entity: Public listing published
Primary listing: OTC: BEIGF
Verification: Partially verified
Last reviewed: 2026-09-13T04:48:09.70381+00:00

Overview

Alpha's canonical identity and public leadership record for BeOne Medicines Ltd..

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

5 public records

Aaron Rosenberg

Chief Financial Officer

State: confirmed
Effective: From Apr 28, 2026
Confidence: 94%
Evidence: BEIGF DEF 14A executive officersApr 28, 2026

Chan Lee

Senior Vice President, General Counsel and Corporate Secretary

State: confirmed
Effective: From Apr 28, 2026
Confidence: 94%
Evidence: BEIGF DEF 14A executive officersApr 28, 2026

John V. Oyler

Co-Founder, Chairman and Chief Executive Officer

State: confirmed
Effective: From Apr 28, 2026
Confidence: 94%
Evidence: BEIGF DEF 14A executive officersApr 28, 2026

Lai Wang

President, Global Head of Research and Development

State: confirmed
Effective: From Apr 28, 2026
Confidence: 94%
Evidence: BEIGF DEF 14A executive officersApr 28, 2026

Xiaobin Wu

President and Chief Operating Officer

State: confirmed
Effective: From Apr 28, 2026
Confidence: 94%
Evidence: BEIGF DEF 14A executive officersApr 28, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 13, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.